- Home
- COOK vs UPB Comparison
COOK vs UPB Comparison
Compare COOK & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOK
- UPB
- Stock Information
- Founded
- COOK 1985
- UPB 2021
- Country
- COOK United States
- UPB United States
- Employees
- COOK N/A
- UPB N/A
- Industry
- COOK Wholesale Distributors
- UPB
- Sector
- COOK Consumer Discretionary
- UPB
- Exchange
- COOK Nasdaq
- UPB NYSE
- Market Cap
- COOK 406.5M
- UPB 457.2M
- IPO Year
- COOK 2021
- UPB 2024
- Fundamental
- Price
- COOK $2.26
- UPB $7.98
- Analyst Decision
- COOK Buy
- UPB Strong Buy
- Analyst Count
- COOK 5
- UPB 4
- Target Price
- COOK $4.10
- UPB $56.50
- AVG Volume (30 Days)
- COOK 115.0K
- UPB 245.5K
- Earning Date
- COOK 03-06-2025
- UPB 03-04-2025
- Dividend Yield
- COOK N/A
- UPB N/A
- EPS Growth
- COOK N/A
- UPB N/A
- EPS
- COOK N/A
- UPB N/A
- Revenue
- COOK $598,914,000.00
- UPB $2,207,000.00
- Revenue This Year
- COOK $1.02
- UPB N/A
- Revenue Next Year
- COOK $4.69
- UPB N/A
- P/E Ratio
- COOK N/A
- UPB N/A
- Revenue Growth
- COOK 3.17
- UPB 82.10
- 52 Week Low
- COOK $1.97
- UPB $6.65
- 52 Week High
- COOK $3.97
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- COOK 34.08
- UPB N/A
- Support Level
- COOK $2.37
- UPB N/A
- Resistance Level
- COOK $2.52
- UPB N/A
- Average True Range (ATR)
- COOK 0.09
- UPB 0.00
- MACD
- COOK -0.01
- UPB 0.00
- Stochastic Oscillator
- COOK 14.56
- UPB 0.00
About COOK Traeger Inc.
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.